Glucosamine, Blood Sugar and Diabetes

Table of Contents

1. Why a Sugar-Derived Molecule Raises the Question
2. The Hexosamine Pathway: The Cell's Glucose Sensor
3. How Glucosamine Slips Past the Control Point
4. What Happened in Animals
5. Glucosamine Infused Into Human Veins
6. Glucosamine by Mouth: Studies That Point Both Ways
7. What the Reviews Concluded
8. Newer Findings: Glucose Toxicity and the UK Biobank
9. Why a Lower-Risk Association Does Not Prove Benefit
10. Who the Research Raises Concerns For
11. What to Know If You Already Take Glucosamine
12. Key Research Papers
13. Connections
14. Featured Videos

Why a Sugar-Derived Molecule Raises the Question

Glucosamine is sold mainly as a joint supplement, usually at 1,500 mg a day. Few people who buy it think of it as a sugar. Chemically, though, it is glucose with one of its oxygen groups swapped for a nitrogen group — an "amino sugar." The body does not need to get it from food or pills. Every cell makes its own, starting from glucose, adding a nitrogen taken from the amino acid glutamine, and spending energy (ATP) along the way. That process is described step by step on the sibling page How the Body Makes Glucosamine.

The concern about blood sugar does not come from the sugar content of a capsule, which is trivial. It comes from where glucosamine lands once it is inside a cell. Glucosamine is the product of a side road off the main glucose-burning route, and in the early 1990s researchers discovered that this side road works as a signal: the more traffic it carries, the less a cell responds to insulin. A supplement that pours glucosamine straight onto that road could, in principle, send a false "too much sugar" message.

Whether that actually happens at the doses people swallow is the real question, and the human evidence is mixed. The sections below lay out both sides before summarising who the research raises concerns for.

Back to Table of Contents

The Hexosamine Pathway: The Cell's Glucose Sensor

When glucose enters a cell, nearly all of it is burned or stored. A small share is diverted into what scientists call the hexosamine biosynthesis pathway. In a 2006 review, Maria Buse described it as "a relatively minor branch of glycolysis." Its first step converts fructose 6-phosphate (a glucose breakdown product) into glucosamine 6-phosphate, and that step is run by a single enzyme with a long name: glutamine:fructose-6-phosphate amidotransferase, shortened to GFAT. GFAT is the first and rate-limiting enzyme — the gatekeeper that decides how much glucose enters the pathway.

The main end product is a molecule called UDP-GlcNAc. It has two jobs. It is a building block for the sugar chains attached to proteins and fats (including the cartilage molecules glucosamine is marketed for), and it is the raw material for a chemical tag called O-GlcNAc, which the cell clips on and off thousands of its own proteins. Buse also noted that UDP-GlcNAc feeds back to regulate GFAT, so the pathway normally keeps its own flow in check.

Gerald Hart and colleagues, writing in Nature in 2007, described O-GlcNAc cycling as a "nutrient and stress sensor." On some proteins the O-GlcNAc tag competes directly with phosphate tags — the switches that insulin uses to send its signal — and the authors noted emerging evidence that O-GlcNAc has a role in diabetes.

Steven Marshall's group, who discovered the link, summarised the idea in 1991: the hexosamine pathway "serves as a glucose sensor coupled to a negative feedback system that can limit the extent of glucose uptake." In plain terms, when a cell sees too much glucose flowing down this side road, it turns down its sensitivity to insulin to protect itself. Donald McClain and Errol Crook reviewed the evidence in 1996 and concluded that excess hexosamine flux causes insulin resistance in cultured cells, tissues and intact animals, and that GFAT activity tracked glucose disposal rates in healthy humans and in transgenic mice.

The strongest single experiment came from the same group in 1996. Lloyd Hebert and colleagues bred mice that made extra GFAT in their muscle and fat. A 2.4-fold rise in GFAT activity in muscle was enough to make the mice insulin resistant: during a clamp test they disposed of glucose at 68.5 mg/kg per minute against 129.4 in their normal littermates, and their muscles carried less of the insulin-responsive glucose transporter GLUT4.

Buse's review is careful to add that, in humans, a causal link between this pathway and insulin resistance "has not been established" — the evidence in people is correlation. That caveat matters for everything below.

Back to Table of Contents

How Glucosamine Slips Past the Control Point

GFAT is the gate. Glucose has to pass through it; glucosamine does not. Once glucosamine is inside a cell it is converted to glucosamine 6-phosphate — the product GFAT would have made — so it joins the pathway after the gatekeeper and its feedback brake.

Marshall, Bacote and Traxinger showed this directly in 1991, in fat cells grown in the laboratory. They first found that insulin resistance in these cells required three ingredients together: glucose, insulin and glutamine. Drugs that block GFAT prevented it. Then they added glucosamine instead of extra glucose:

• Five hours of glucosamine exposure produced a 40–50% loss of the cells' response to insulin.
• Glucosamine did this without needing glutamine, and blocking GFAT did not stop it — proof that it entered the pathway beyond the gate.
• Glucosamine entered the cells at only a quarter of the rate of glucose, yet worked at a dose ten times lower. The authors estimated it was at least 40 times more potent than glucose at causing this insulin resistance.

From that day on, glucosamine became the standard laboratory tool for switching on the hexosamine pathway "independently of glucose" — the phrase the Monauni team used in 2000. The very property that makes it useful to researchers is the one that raises the question for people with blood-sugar problems.

One important limit: laboratory concentrations were far higher than anything measured in human blood after a supplement (see the oral studies below).

Back to Table of Contents

What Happened in Animals

Luciano Rossetti and colleagues tested the idea in living, conscious rats in 1995. They infused glucosamine into the bloodstream for 7 hours while holding blood sugar steady with an insulin clamp. The infusion raised blood glucosamine to about 1.2 mM and pushed UDP-GlcNAc in muscle and liver up 4- to 5-fold.

• In rats with normal blood sugar, glucosamine sharply cut the amount of glucose their tissues took up under insulin (from 44.1 to 30.4 mg/kg per minute) — what the authors called "severe skeletal muscle insulin resistance."
• The same happened in diabetic rats whose blood sugar had been brought down to normal with a drug.
• In diabetic rats that were still hyperglycemic, glucosamine had no extra effect.

That last result is telling. It suggests that in uncontrolled diabetes the pathway is already running flat out on the body's own glucose, so adding glucosamine cannot push it further — which supports the view that the hexosamine pathway is part of how high blood sugar causes insulin resistance in the first place.

These were intravenous doses in rats. A review by James Anderson and colleagues in 2005 noted that oral glucosamine at large doses in animals had "no documented effects on glucose metabolism." The route matters.

Back to Table of Contents

Glucosamine Infused Into Human Veins

Two research groups tried glucosamine infusions in healthy volunteers around the year 2000. Their results did not agree.

Monauni and colleagues (2000) gave 10 healthy people an intravenous glucosamine infusion at a low or high rate and ran glucose-tolerance and insulin-clamp tests. Glucosamine:

• raised fasting blood glucose by roughly 0.3–0.5 mmol/L (about 5–9 mg/dL);
• raised the glucose level at which the pancreas starts releasing insulin by about 0.5–0.8 mmol/L;
• at the high rate, cut insulin sensitivity measured during the tolerance test by about 30% and glucose's own ability to clear itself by about 40%.

The authors concluded that "acute GlcN infusion recapitulates some metabolic features of human diabetes." They also noted that insulin-driven glucose use during the clamp itself did not change, and that it remained to be shown whether the pathway causes insulin resistance in people with normal blood sugar.

Pouwels and colleagues (2001) took a different approach in 18 healthy people: they infused glucosamine into the artery of one forearm for up to 5 hours and compared that arm with the other. Glucosamine levels in the infused arm reached 0.42–0.81 mmol/L, yet insulin-stimulated glucose uptake was the same in both arms and in a placebo group. Their conclusion: the results "do not support involvement of the hexosamine pathway in the regulation of insulin sensitivity in humans, at least not in the short-term setting."

So, by vein, one study saw diabetes-like changes and the other saw none in forearm muscle over a few hours. Neither used the oral doses people actually take.

Back to Table of Contents

Glucosamine by Mouth: Studies That Point Both Ways

The studies that matter most for a supplement user are the ones in which people swallowed ordinary doses. They split into two groups.

Studies that found a worsening

• Pham 2007: 38 volunteers with no known glucose problem took 1,500 mg of glucosamine a day for 6 weeks. HOMA-IR, a standard insulin-resistance score calculated from fasting glucose and insulin, rose from 2.8 to 3.2 (P < 0.04). Small-artery elasticity fell, most in those with the poorest insulin sensitivity at the start. Each person was compared with their own starting values rather than with a placebo group, which limits the conclusion. The authors wrote that people "with underlying poorer insulin sensitivity are at risk for worsening insulin resistance."
• Biggee 2007: 16 people with osteoarthritis drank 75 g of glucose with or without 1,500 mg of glucosamine sulphate. Three of them turned out to have previously undiagnosed glucose intolerance, and in those three glucosamine produced significantly higher glucose rises (p = 0.04). The other 13 also had higher average rises, but not significantly (p = 0.20). Insulin levels did not change. The authors suggested glucosamine may affect glucose levels in people with untreated diabetes or glucose intolerance.

Studies that found no change

• Muniyappa 2006: a randomised, placebo-controlled, double-blind crossover trial in 20 lean and 20 obese adults, 500 mg three times a day for 6 weeks, with insulin sensitivity measured by the gold-standard clamp. Glucosamine did not cause insulin resistance or blood-vessel dysfunction in lean people and did not significantly worsen them in obese people.
• Scroggie 2003: a placebo-controlled trial in people with well-controlled type 2 diabetes, most on one or two diabetes drugs, who took 1,500 mg glucosamine hydrochloride plus 1,200 mg chondroitin daily for 90 days. HbA1c did not change.
• Gommans 2017: 407 overweight or obese middle-aged women were randomised to glucosamine sulphate or placebo for 2.5 years and followed for 6.5 years. There was no significant effect on HbA1c or on new diabetes. Women who started with a high HbA1c (42 mmol/mol or above) had higher odds ratios than those with a normal HbA1c, though this did not reach significance.

Why oral doses may behave differently

Biggee and colleagues measured blood glucosamine after a 1,500 mg dose of glucosamine sulphate in 2006. Levels peaked 90–180 minutes later at 1.9–11.5 micromol/L. For comparison, Marshall's fat cells responded at a half-maximal concentration of 0.36 mM (360 micromol/L), and Rossetti's rats were infused to about 1.2 mM (1,200 micromol/L). Muniyappa found a blood half-life of about 150 minutes. Oral glucosamine therefore reaches the blood at a small fraction of the levels that caused clear insulin resistance in the laboratory and in animals — the strongest argument that the supplement is harmless to blood sugar.

Back to Table of Contents

What the Reviews Concluded

Four reviews have weighed this evidence. They read the same studies and lean in different directions.

• Anderson 2005 reviewed trial data on 3,063 people and found fasting glucose fell slightly after about 66 weeks of oral glucosamine. It noted that laboratory studies used concentrations 100–200 times higher than expected tissue levels, and concluded glucosamine "does not affect glucose metabolism."
• Stumpf 2006 found no documented changes in glucose control in the oral trials, but stressed that data in people with diabetes were limited, and recommended close monitoring for changes in glucose control.
• Dostrovsky 2011, a systematic review of 11 studies, found that 4 reported decreased insulin sensitivity or increased fasting glucose, 3 of them with oral glucosamine. Crucially, studies that included people with impaired glucose tolerance or insulin resistance at the start were more likely to detect an effect. It called the evidence mixed and asked for more studies in exactly those high-risk people.
• Simon 2011 concluded glucosamine has no effect on fasting glucose, glucose metabolism or insulin sensitivity at any oral dose — while also acknowledging that "no definitive long-term studies of GlcN use for individuals with pre-diabetes are available."

The fair summary: in people with normal blood sugar, most oral studies find no harm. The signals of harm cluster in people whose glucose control was already impaired — the very group for whom long-term trials are missing.

Back to Table of Contents

Newer Findings: Glucose Toxicity and the UK Biobank

Glucosamine as the link between high sugar and damage (Riahi 2026)

A 2026 study in JCI Insight by Yael Riahi, Gil Leibowitz and colleagues asked why chronically high blood sugar wears out the insulin-making beta cells of the pancreas and damages the kidney. Using labelled glucose in diabetic rodents, they found that glucose levels in tissue strongly correlated with glucosamine — the body's own, made from that glucose. A similar link between blood glucose and glucosamine held in humans with and without type 2 diabetes, and higher glucosamine went with poorer beta-cell function.

In cells in the laboratory, low-dose glucosamine switched on a growth-signalling hub called mTORC1 in pancreatic islets and kidney tubule cells, through O-GlcNAc tagging, and in beta cells it brought on oxidative stress, ER stress and loss of their specialised identity. Blocking this glucosamine/mTORC1 route — genetically, or with an SGLT2-inhibitor diabetes drug that lowers glucose — eased beta-cell stress and improved glucose control in the animals. The authors call the glucosamine/mTORC1 pathway "an important mediator of β cell and kidney dysfunction in diabetes."

To be precise about what this shows: the study is about glucosamine the body makes from excess glucose, not about supplements. It does not test whether a capsule adds to that load. What it does is put glucosamine itself, not just the pathway, at the centre of how high blood sugar causes harm — which raises a question about adding more for someone whose glucose is already high.

Large observational studies point the other way

Three analyses of the UK Biobank, a cohort of several hundred thousand British adults who reported their supplement use, found that glucosamine users did better:

• Ma 2020: among 404,508 people free of diabetes, glucosamine users had a 17% lower risk of developing type 2 diabetes over a median 8.1 years (hazard ratio 0.83, 95% CI 0.78–0.89), after adjusting for age, BMI, lifestyle and other factors.
• Zhang 2026: among 54,096 people who already had prediabetes or diabetes, glucosamine use went with a lower risk of cardiovascular events (hazard ratio 0.94 overall; heart failure 0.89; ischaemic heart disease 0.89; stroke 0.86) over a median 10.56 years.
• Hayward 2025: among 436,200 people, glucosamine users were more likely to be in a lower urine-albumin group (odds ratio 0.81), an early marker of kidney and blood-vessel health. But a Mendelian randomisation analysis — a genetic method designed to test cause and effect — found little evidence of a causal link (p = 0.60), and the authors wrote that whether the relationship "is causal or confounded remains unclear."

These findings are real and belong in the picture. The next section explains why they do not settle the matter.

Back to Table of Contents

Why a Lower-Risk Association Does Not Prove Benefit

The UK Biobank studies are observational: they compare people who chose to take glucosamine with people who did not. That design cannot separate the effect of the supplement from the kind of person who takes it.

• The healthy-user effect. People who buy joint supplements tend to be more health-conscious in many unmeasured ways — how they eat, how active they stay, how often they see a doctor. Adjusting for known factors such as BMI and smoking reduces this bias but cannot remove what was not measured.
• Self-report. Glucosamine use was recorded from a questionnaire at one point in time. Dose, form, duration and whether people kept taking it over the following decade are unknown.
• The genetic test did not back it up. Hayward 2025 used Mendelian randomisation precisely to test causation, and found little evidence for it. The authors also explained why genetic stand-ins for supplement use are hard to build.
• Randomised trials did not show the benefit. In the one long randomised trial with blood-sugar outcomes, Gommans 2017, glucosamine did not lower new diabetes or HbA1c. If glucosamine truly cut diabetes risk by a sixth, a placebo-controlled trial is where that would be expected to show up.

An association can point researchers toward a question. It is not evidence that a pill will lower a particular person's blood sugar or protect their heart.

Back to Table of Contents

Who the Research Raises Concerns For

The research raises its clearest blood-sugar concern for people in the following groups:

• People with type 1 or type 2 diabetes.
• People with prediabetes.
• People with a high fasting blood glucose.
• People with an elevated HbA1c.
• People with known insulin resistance (for example a raised HOMA-IR score, metabolic syndrome or polycystic ovary syndrome with insulin resistance).

Why — and how strong the evidence is

The concern rests on a chain of evidence, not a single proof:

1. Glucosamine enters the cell's glucose-sensing pathway past its control point, GFAT, and was at least 40 times more potent than glucose at causing insulin resistance in fat cells (Marshall 1991).
2. Pushing more flux through that pathway causes insulin resistance in animals (Rossetti 1995; Hebert 1996).
3. Intravenous glucosamine raised fasting glucose in healthy people (Monauni 2000).
4. Oral 1,500 mg a day raised HOMA-IR in an uncontrolled 6-week study (Pham 2007), and glucose rose after a dose in people with undiagnosed glucose intolerance (Biggee 2007).
5. The reviews agree that harm signals cluster in people with impaired glucose control, and that long-term trials in prediabetes do not exist (Dostrovsky 2011; Simon 2011).
6. Glucosamine made from excess glucose has now been linked to beta-cell and kidney damage in diabetes (Riahi 2026).

The human data are mixed: well-run trials such as Muniyappa 2006, Scroggie 2003 and Gommans 2017 found no worsening. So the concern is not proven. What the evidence shows is a balance: on one side a plausible risk, concentrated in people whose blood sugar is already struggling; on the other, very little benefit. In the largest joint trial, GAIT (Clegg 2006, 1,583 people), the response rate on glucosamine was only 3.9 percentage points above placebo and not statistically significant, and the 2019 American College of Rheumatology guideline strongly recommends against glucosamine for knee and hip osteoarthritis, with the 2019 OARSI guideline also not recommending it. The details are on Glucosamine for Joint Pain: What the Trials Found. With the measured benefit close to zero, there is little on the other side of the scale to offset even a modest, uncertain risk.

The body already makes all the glucosamine it needs from glucose and glutamine. For an honest look at whether glutamine is a better choice for blood sugar, see Glutamine Instead of Glucosamine?

Back to Table of Contents

What to Know If You Already Take Glucosamine

• Decisions about medicines and supplements belong with a clinician, especially for people on diabetes medicines or the blood thinner warfarin. Glucosamine's other interactions are covered on Glucosamine Safety.
• The numbers that track this. A fasting glucose and an HbA1c test show where glucose control stands. For people with diabetes who monitor at home, a 2006 pharmacy review (Stumpf) recommended close monitoring for a change in readings after starting or stopping glucosamine.
• Nothing on this page is a reason to change diabetes medicines. Glucosamine is a supplement; diabetes treatment is prescribed medicine, and changes to it belong with the prescriber.
• Medication lists. Supplements are often left off medication lists, so a prescriber may not know glucosamine is being taken.
• Glucose or HbA1c in the prediabetes or diabetes range. This is the group in which the research's blood-sugar signals cluster and long-term trials are missing; whether to continue is a question for a clinician.

Blood sugar responds far more to whole-food eating, movement, sleep and weight than to any joint supplement. The Blood Sugar section and Insulin Resistance pages cover those levers.

Back to Table of Contents

Key Research Papers

1. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706-4712. — PubMed PMID: 2002019
2. Marshall S, Garvey WT, Traxinger RR. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J. 1991;5(15):3031-3036. — doi:10.1096/fasebj.5.15.1743436 (PubMed PMID: 1743436)
3. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab. 2006;290(1):E1-E8. — doi:10.1152/ajpendo.00329.2005 (PubMed PMID: 16339923)
4. McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes. 1996;45(8):1003-1009. — doi:10.2337/diab.45.8.1003 (PubMed PMID: 8690144)
5. Hebert LF Jr, Daniels MC, Zhou J, et al. Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest. 1996;98(4):930-936. — doi:10.1172/JCI118876 (PubMed PMID: 8770864)
6. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017-1022. — doi:10.1038/nature05815 (PubMed PMID: 17460662)
7. Rossetti L, Hawkins M, Chen W, et al. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest. 1995;96(1):132-140. — doi:10.1172/JCI118013 (PubMed PMID: 7615783)
8. Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes. 2000;49(6):926-935. — doi:10.2337/diabetes.49.6.926 (PubMed PMID: 10866044)
9. Pouwels MJ, Jacobs JR, Span PN, et al. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab. 2001;86(5):2099-2103. — doi:10.1210/jcem.86.5.7470 (PubMed PMID: 11344213)
10. Pham T, Cornea A, Blick KE, et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci. 2007;333(6):333-339. — doi:10.1097/MAJ.0b013e318065bdbe (PubMed PMID: 17570985)
11. Biggee BA, Blinn CM, Nuite M, et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis. 2007;66(2):260-262. — doi:10.1136/ard.2006.058222 (PubMed PMID: 16818461)
12. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes. 2006;55(11):3142-3150. — doi:10.2337/db06-0714 (PubMed PMID: 17065354)
13. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med. 2003;163(13):1587-1590. — doi:10.1001/archinte.163.13.1587 (PubMed PMID: 12860582)
14. Gommans YMM, Runhaar J, Jacobs ML, et al. The effect of prolonged glucosamine usage on HbA1c levels and new-onset diabetes mellitus in overweight and obese middle-aged women. Am J Med. 2017;130(6):731-737.e6. — doi:10.1016/j.amjmed.2016.11.038 (PubMed PMID: 28011309)
15. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65(2):222-226. — doi:10.1136/ard.2005.036368 (PubMed PMID: 16079170)
16. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 2005;43(2):187-201. — doi:10.1016/j.fct.2004.11.006 (PubMed PMID: 15621331)
17. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother. 2006;40(4):694-698. — doi:10.1345/aph.1E658 (PubMed PMID: 16569816)
18. Dostrovsky NR, Towheed TE, Hudson RW, et al. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthritis Cartilage. 2011;19(4):375-380. — doi:10.1016/j.joca.2011.01.007 (PubMed PMID: 21251987)
19. Simon RR, Marks V, Leeds AR, et al. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev. 2011;27(1):14-27. — doi:10.1002/dmrr.1150 (PubMed PMID: 21218504)
20. Riahi Y, Kogot-Levin A, Teselpapa Z, et al. Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes. JCI Insight. 2026;11(10):e197331. — doi:10.1172/jci.insight.197331 (PubMed PMID: 42171606)
21. Ma H, Li X, Zhou T, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2020;43(4):719-725. — doi:10.2337/dc19-1836 (PubMed PMID: 31988063)
22. Zhang Z, Liu Y, Pan L, et al. Association of habitual glucosamine use with cardiovascular disease among individuals with prediabetes and diabetes: a prospective cohort study from the UK Biobank. J Integr Complement Med. 2026;32(8):659-667. — doi:10.1177/27683605261418094 (PubMed PMID: 41712318)
23. Hayward SJ, Constantinescu A, Hazelwood E, et al. Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study. BMJ Open. 2025;15(11):e096344. — doi:10.1136/bmjopen-2024-096344 (PubMed PMID: 41271412)
24. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. — doi:10.1056/NEJMoa052771 (PubMed PMID: 16495392)
25. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233. — doi:10.1002/art.41142 (PubMed PMID: 31908163)
26. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. — doi:10.1016/j.joca.2019.06.011 (PubMed PMID: 31278997)

PubMed Topic Searches

1. Glucosamine and insulin resistance
2. Oral glucosamine and glucose metabolism in humans
3. Hexosamine biosynthesis pathway and diabetes
4. Glucosamine and HbA1c
5. Glucosamine in the UK Biobank

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

• All Amino Acids
• Glucosamine
• How the Body Makes Glucosamine
• Glutamine Instead of Glucosamine?
• Glucosamine for Joint Pain
• Glucosamine Safety
• History of Glucosamine
• Glutamine
• How the Body Makes Glutamine
• Diabetes
• Type 2 Diabetes
• Prediabetes
• Insulin Resistance
• Hemoglobin A1C
• HOMA-IR
• Fasting Insulin
• Blood Sugar
• Diabetic Nephropathy
• Insulin Signalling and GLUT4 (animation)
• Osteoarthritis

Back to Table of Contents

Featured Videos